Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

TAK-580 Program Presentations

Download a presentation for more information.
Adobe® Reader®

Phase 1 study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors or melanoma: Final analysis
2017 European Society for Medical Oncology (ESMO) Congress
Madrid, Spain
September 8–12, 2017
Download (PDF, 1092KB)

Phase I Study of Two Dosing Schedules of the Investigational Oral Pan-RAF Kinase Inhibitor TAK-580 (MLN2480) in Patients with advanced Solid Tumors or Melanoma
18th ECCO – 40th ESMO European Cancer Congress
Vienna, Austria
September 25-29, 2015
Download (PDF, 320KB)

First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Barcelona, Spain
November 18-21, 2014
Download (PDF, 6593KB)

Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure-adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Barcelona, Spain
November 18-21, 2014
Download (PDF, 7037KB)

BIIB024, a potent pan-RAF kinase inhibitor for melanoma and solid tumors
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics
Berlin, Germany
November 16-19, 2010
Download (PDF, 620KB)